Sun Hui-Chuan, Tang Zhao-You
Liver Cancer Institute and Zhong Shan Hospital, Fudan University, #136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China.
J Cancer Res Clin Oncol. 2004 Jun;130(6):307-19. doi: 10.1007/s00432-003-0530-y. Epub 2004 Mar 18.
Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. Many angiogenic factors have been studied in HCC, and several anti-angiogenic therapies have been tested in animal models and patients. This paper summarizes the latest findings, especially regarding the clinical significance of endothelial cell markers and angiogenic factors in HCC, and experimental and clinical anti-angiogenesis therapies. Further developments in this area, such as endothelial cell-oriented research and better experimental and clinical designs in the evaluation of anti-angiogenic therapies are discussed.
肝细胞癌（HCC）是一种典型的富血管肿瘤。在HCC中已经对许多血管生成因子进行了研究，并且在动物模型和患者中测试了几种抗血管生成疗法。本文总结了最新的研究结果，特别是关于内皮细胞标志物和血管生成因子在HCC中的临床意义，以及实验性和临床抗血管生成疗法。还讨论了该领域的进一步发展，例如以内皮细胞为导向的研究以及在抗血管生成疗法评估中更好的实验和临床设计。
